[Skip to Content]
[Skip to Content Landing]

Perioperative Medication Management

Learning Objectives
1. Analyze the risks and benefits underlying perioperative management of antiplatelet and anticoagulation medications
2. Recognize the importance of continuing most cardiovascular medications perioperatively
3. Recognize the importance of continuing most pulmonary medications perioperatively
4. Assess when stress dose steroids are indicated and manage other endocrine medications in the perioperative period
5. List the theoretical risks of continuing neuropsychiatric medications and decide whether or not to discontinue them
6. Identify and discontinue herbal medications that may adversely impact perioperative outcomes
7. Analyze the risks and benefits underlying perioperative management of antirheumatic medications
2 Credits CME

Although general internists and subspecialists are familiar with prescribing and managing medications in typical outpatient and inpatient venues, the perioperative period represents a challenging and often unfamiliar setting. This module will outline the principles, available evidence, and expert opinions to be considered when making perioperative management recommendations for some of the most commonly prescribed medications.

Please finish the activity before taking the quiz.
Close

Sign in to take quiz and track your certificates

Society of Hospital Medicine Education

SHM Consults: Perioperative And Consultative Medicine curriculum can help you feel more confident about your knowledge and skills related to consultative medicine. Learn more

Activity Information

© 2020 Society of Hospital Medicine | (SHM) All Rights Reserved

Accreditation Statement: The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Statement Designator: The Society of Hospital Medicine designates this activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Author: Dr. Cohn reports having minor stock holdings in Bristol Myers Squibb, GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc; and serving on the Advisory Board for Portola and Speaker Honoria for Janssen.

Editors (Leonard Feldman MS, FACP, SFHM and Kurt Pfeifer MD, FACP, SFHM): Dr. Feldman reports having no relevant financial or advisory relationships with corporate organizations related to this activity. Dr. Pfeifer reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

SHM COI Policy: In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.

Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in health care and not those of a commercial interest.

Close
Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
Close